The Zephyr valve is a device that can improve breathing in people with emphysema, one of the two most common types of chronic obstructive pulmonary disease (COPD). The valve received approval by the ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the publication of long ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx Corporation, a leader in therapeutic pulmonary device technologies, announced today that UnitedHealthcare®, the largest commercial insurer in the United ...
Two New Programs Aim to Improve Awareness and Support for Patients with Severe COPD/Emphysema REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Pulmonx Corporation (LUNG) (Nasdaq: LUNG) (“Pulmonx”), a global ...
Over 20,000 Patients Treated with the Non-Surgical Zephyr Valve for Severe Emphysema, a Form of COPD
REDWOOD CITY, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- As part of COPD Awareness Month, Pulmonx Corporation is announcing that over 20,000 patients have been treated worldwide with their Zephyr® ...
The US Food and Drug Administration (FDA) has approved the Zephyr Endobronchial Valve (Pulmonx Corp) to treat breathing difficulty associated with severe emphysema. "Treatment options are limited for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback